Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) — Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next-generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration. The announcement was made ahead of their official showcase at the Hawaiian Eye and Retina 2024 Meeting from January 13-19, 2024.
Related news for (IRIX)
- Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
- Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
- Iridex Announces Strategic Investment in the Company
- Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024
- Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management